ABL Bio Licenses Grabody-B Platform to GSK for Brain Drugs
ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases Programs will leverage ABL Bio’s Grabody-B platform technology to effectively deliver molecules across...